Influence of Sorafenib and Bevacizumab on pancreatic volume – A monocentric CT based analysis

Keyphrases

• Sorafenib 100%
• Bevacizumab 100%
• Pancreatic Volume 100%
• Monocentric 100%
• CT Analysis 100%
• Vascular Endothelial Growth Factor 60%
• Tyrosine Kinase Inhibitor 60%
• Irinotecan 40%
• Pancreas 40%
• Computed Tomography 20%
• Volumetry 20%
• Tyrosine Kinase 20%
• Growth Factor Signaling 20%
• Diarrhea 20%
• Angiogenesis 20%
• Tumor Metastasis 20%
• Volume Reduction 20%
• Angiogenesis Inhibitors 20%
• Tumor Growth 20%
• Pancreatic Malignancy 20%
• Humanized 20%
• Pancreatic Insufficiency 20%
• Monoclonal Immunoglobulin 20%
• Immunoglobulin G1 20%
• Anti-angiogenetic 20%
• Volume Decrease 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Sorafenib 100%
• Bevacizumab 100%
• Vasculotropin 60%
• Protein Tyrosine Kinase Inhibitor 60%
• Irinotecan 40%
• Growth Factor 20%
• Side Effect 20%
• Tumor Growth 20%
• Diarrhea 20%
• Protein Tyrosine Kinase 20%
• Immunoglobulin G1 Antibody 20%
• Paraprotein 20%
• Pancreatic Insufficiency 20%
• Angiogenesis Inhibitor 20%